



## **Statement: Biogen Shares Update on Angelman Syndrome Program**

May 16, 2024

**May 16, 2024** – In addition to discontinuing development of BIIB105, an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS), Biogen has elected not to exercise its option to license and lead development of BIIB121, an ASO designed to restore expression of ubiquitin-protein in patients with Angelman syndrome.